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Graves’s disease is the most common cause of 
hyperthyroidism. There are three current therapeutic options: 
anti-thyroid medication, surgery, and radioactive iodine (I 
131). There are few data in the literature regarding the effects 
of radioiodine therapy on the larynx and voice. The aim and 
the Aim: os this study was: to assess the effect of radioiodine 
therapy on the voice of Basedow-Graves patients. Material 
and Method: A prospective study was done. Following the 
diagnosis of Grave´s disease, patients underwent investigation 
of their voice, measurement of maximum phonatory time 
(/a/) and the s/z ratio, fundamental frequency analysis (Praat 
software), laringoscopy and (perceptive-auditory) analysis 
in three different conditions: pre-treatment, 4 days, and 20 
days post-radioiodine therapy. Conditions are based on the 
inflammatory pattern of thyroid tissue (Jones et al. 1999). 
Results: No statistically significant differences were found in 
voice characteristics in these three conditions. Conclusion: 
Radioiodine therapy does not affect voice quality.
Keywords: graves’s disease, hyperthyroidism, iodine 
radioisotopes, voice.
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INTRODUCTION
Basedow Graves’s (GD) Disease may be characte-
rized by the presence of the TSH-receptor autoantibodies 
(TRAb),1,2 which generate the typical features of diffuse 
goiter, at times developing ophthalmic disease, and rarely, 
Graves’s dermatopathy.3 All of the clinical manifestations 
of this disease results from the systemic increase in thyroid 
hormones and their resulting effect on organs and systems.4 
The main complaints, other than goiter, are the following: 
anxiety, tremors, tachycardia, weight loss, diarrhea, heat 
intolerance, fatigue and dyspnea.3 The diagnosis is made 
based on clinical findings, and is confirmed by the pre-
sence of TRAb, suppression of TSH, and elevation of free 
thyroxin (free T4), total thyroxin (total T4) and triiodine-
thyronin (T3).1,3,4 
There is increased production of carbon dioxide in 
hyperthyroidism, which activates all of the mechanisms 
that increase the frequency and depth of breathing.5 Incre-
ased basal metabolism in hyperthyroid patients leads to a 
higher consumption of oxygen, vasodilatation and incre-
ased blood flow.6 In addition to metabolic changes, the 
pathologically enlarged gland may exert pressure on the 
trachea and the recurrent laryngeal nerve, which results in 
dysphagia, respiratory difficulty and noisy breathing.7,8 
GD is the most common form of hyperthyroidism. 
There are currently three approaches to this disease: 
anti-thyroid medication, surgery in selected cases, and 
radioactive iodine (I131) therapy.5 
Anti-thyroid medications are the first line treatment 
in patients with mild disease, small goiters, children, 
teenagers, and in special conditions such as pregnancy. 
I131, on the other hand, is being used increasingly; it is 
a liquid for oral use and is considered a safe, definitive, 
inexpensive and easily applied treatment.9 Other effects 
of I131 include early induction of hypothyroidism due to 
radioactive thyroid tissue destruction. Follicular cells are 
eliminated by ß radiation, which penetrates from 1 to 2m 
and destroys the cells that take it up, as well as adjacent 
cells.10,11 Radiation thyroiditis tends to develop during the 
first few weeks of treatment; it is evidenced by epithelial 
edema, follicular derangement and necrosis, and a mono-
nuclear cell infiltrate.6 Fibrosis, narrowing of vessels and, 
eventually, lymphocyte infiltration follow resolution of the 
acute phase. There have been few reports in the literature 
about the effects of radioactive iodine on the larynx and, 
consequently, on voice.
A case was described in 1978 about a woman who 
received a dose of 7 mCi; one week later she developed 
hoarseness, which laryngoscopy revealed as being due 
to right vocal fold paresis. The author stated that paresis 
might occur as an uncommon complication, and that only 
one other case had been described (in 1972).12 We found a 
recent paper that described vocal fold paralysis following 
I131 therapy in a 75-year-old woman who developed 
hoarseness one week following treatment; indirect laryn-
goscopy in this patient revealed right vocal fold paralysis. 
The author raised the hypothesis that vocal fold paralysis 
was secondary to a mechanical stretching mechanism of 
the recurrent laryngeal nerve, which itself resulted from 
focal edema of the adjacent tissues.13 
The relation between the thyroid and the recurrent 
laryngeal nerve is well known, especially when voice 
changes take place following thyroidectomy, due to han-
dling of the nerve.14 
No study has been published assessing any possible 
relation between radioactive iodine and the larynx and 
voice of hyperthyroidic patients. Individuals who use their 
voice professionally have raised this issue, as well as their 
concerns about the effect of treatment.
 OBJECTIVE
Given the literature we investigated and the pauci-
ty of studies investigating in depth the effects of thyroid 
dysfunction and radioactive iodine treatment on voice, we 
decided to assess the acute effects of radioactive iodine-
induced laryngeal changes on voice in GD hyperthyroidic 
patients.
MATERIAL AND METHOD
This study was approved by the Research Ethics 
Committee for research on human beings at the institu-
tion in which it was undertaken; the protocol number 
was 023/04.
Forty-five GD hyperthyroidic patients from the 
Endocrinology and Metabology outpatient unit were inter-
viewed between May 2004 and May 2005, and referred to 
the Nuclear Medicine unit for radioactive iodine treatment 
(I131) at a mean dose of 20mCi. Of these 45 patients, 13 
were included in this study according to the inclusion/
exclusion criteria.
The inclusion criteria were as follows: GD-diagno-
sed individuals of both sexes, aged between 18 and 50 
years, as first referrals to the Endocrinology and Metabo-
logy unit for radioactive iodine treatment, not undergoing 
or not having undergone voice therapy; only patients that 
came to all of the pre-established evaluation visits were in-
cluded. The exclusion criteria were as follows: individuals 
aged over 50 years, menopause, smokers, ex-smokers, and 
one or more absences from evaluation visits. Patients who 
presented vocal fold nodules or polyps, Reinke’s edema, 
and cysts and/or grooves were also excluded.
The patients were first contacted two days before 
the scheduled day for radioactive iodine therapy to me-
asure their interest in the study, for explanations and for 
clearing doubts. Upon agreement, patients signed a free in-
formed consent form, and were scheduled for assessment. 
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The procedures took place in three separate moments:
Moment 1. Pre-dose (two hours before ingesting 
iodine131)
Moment 2. 4-5 days post-dose
Moment 3. 17-18 days post-dose
The procedures included an interview focusing 
on voice complaints. The next step was a perception of 
voice analysis, in which the maximum phonation time for 
the sustained vowel /a/ was measured; the s/z ratio was 
also calculated. Normal values were 14 seconds for wo-
men and 20 second for men;15 the normal s/z ratio value 
is 1.0 second or less.16 Voice recording was digital. The 
fundamental frequency based on the sustained vowel /a/ 
sample was analyzed using the computer software Praat, 
version 4.2.31. A standard five seconds were extracted from 
the mid-portion of the emission, as follows: between the 
five initial seconds or the final five seconds of the speech 
sample. Following this selection, zoom was applied to 
show and analyze the mean fundamental frequency (Fo) 
in the measurement spectrum.
The fundamental frequency for men was defined 
as 127.61 Hz (standard deviation - 20.26 Hz) and the fun-
damental frequency for women was defined as 215,42Hz 
(standard deviation - 53.85 Hz).17 
Patients underwent videotelelaryngoscopy, in which 
the following were assessed: presence of aryepiglottic fold 
edema, the epiglottis, the vocal folds; vocal fold hypere-
mia; increased vocal fold vascularization, and presence/
absence of glottic closure. The TSH and the T4L were 
measured in all of the moments. The reference ranges for 
these tests are the following: TSH - 0.45 to 4.50 mIU/mL, 
and T4L - 0.7 to 1.6 mIU/mL
The voices of patients were presented to three voice 
specialist speech therapists, who filled in the perception-
hearing assessment protocols individually. There was a 
protocol for each patient, containing sex, age, and sham 
initials. The GRBASI scale was used for voice analysis. 
This scale assesses dysphonia (G) globally based on the 
following features: Roughness (R), Breathiness (B), As-
thenia (A), and Strain (S).16 In 1996, Instability (I)18,19 was 
added. For each of these features the following scores 
may be given: grade 0 (absence), 1 (mild), 2 (moderate) 
and 3 (severe).
The SPSS (Statistical Package for Social Sciences), 
version 13.0, was used for the statistical analysis of the 
sample. The ANOVA test was used for continuous varia-
bles and repeated measures. Cochran’s Q test was used to 
analyze vocal fold vascularization, as this is a dichotomic 
variable. Friedman’s test was used for analyzing the ordinal 
variables edema, vocal fold hyperemia, aryepiglottic fold 
edema, epiglottic or interarythenoid edema. Bonferroni’s 
test was used for multiple corrections. Significance was 
achieved at p ≤ 0.05 (5%) for all of the tests. The analy-
sis was descriptive for the variables voice complaints, 
diagnosis and glottic closure, as these are categoric and 
of low variability in our sample. Krippendorff’s concor-
dance and reliability test was applied to the variables of 
the perception-hearing analysis done by three speech 
therapists, who acted as referees. Alpha significance was 
attained between 0.60 and 0.80, and unconditional alpha 
concordance was attained between 0.80 and 1.00. If there 
was no concordance between the referees the majority 
results were cited and debated.
RESULTS
There was no statistically significant variation in 
both thyroid hormone values, which confirms the absence 
of change from the initial state of hyperthyroidism to the 
moment 3, as shown on Charts 1 and 2.
Chart 1. Progression curve showing the mean values of the thyroid-
stimulating hormone (TSH) in the sample. TSH p=0.493.
Chart 2. Progression curve showing the mean values of the free thyroxin 
hormone (T4L) in the sample on the three moments. T4L p=0.518.
There were no statistically significant variations for 
all of the laryngoscopically evaluated parameters (vocal 
fold edema and hyperemia, aryepiglottic fold edema, 
epiglottic edema, vascularization and presence/absence of 
glottic closure), which indicated linearity in these findings 
and the absence of change in glottic phonation patterns.
Notwithstanding the low rate of agreement between 
the study referees for the GRBASI scale parameters, there 
was no statistically significant variation during and throu-
ghout the three test moments (Table 1).
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 DISCUSSION
The have been few papers published in the lite-
rature about the effects of radioactive iodine therapy on 
voice quality; existing papers report episodes of vocal 
fold paresis due to recurrent laryngeal nerve involvement 
following radioactive iodine therapy.12,13 These studies did 
not investigate other aspects, such as voice parameters, 
in the acute post-treatment (radioactive iodine therapy) 
moments.
The pre-established moments for evaluating the 
patients were chosen according to the inflammation profile 
of thyroid tissue in patients undergoing I131 treatment, 
assessed by direct measurements of cytokines that are 
usually involved in GD.20 The first evaluation took place 
in moment 1 (pre-dose I131); the earliest point of acute 
inflammation occurs in moment 2; the evaluation in mo-
ment 3 reveals the state of vocal folds and voice quality 
during the peak inflammation. During these acute inflam-
matory moments, patients are still hyperthyroidic; there 
is no mixedema, which could cause laryngeal and voice 
changes. We included subjects aged 18 or above until age 
50 years; these subjects have already gone through voice 
change but have not yet felt the effects of presbyphonia, 
which could have masked our results, as applied to voice 
and laryngeal changes.15
Thyroid hormone measurements were made in the 
three moments to analyze each patient’s response to ra-
dioactive iodine therapy and to detect possible hormonal 
variations.
The fact that these patients showed no change in 
TSH and free T4 levels suggests that hormone variations 
should not be considered a cause of voice or laryngeal 
alterations. Hormone alterations develop around 90 days 
after radioactive iodine therapy,21,22 which was taken into 
account to eliminate possible interference on results. Pho-
natory measurements of the vowel /a/ and the s/z ratio 
yielded no statistically significant variations; descriptive 
results reveal that most of the patients had low values, 
probably due to secondary effects to the typical manifes-
tations of hyperthyroidism, such as breathlessness,13 fati-
gue and lack of vocal strength.23 Increased glottic muscle 
performance is needed for theses emissions, which may 
Table 1. Features of the GRBASI scale at each moment. For the GRBASI scale p>0.05.
 Moment  1 Moment  2 Moment  3
Grade  0 2(15%) 2(15%) 3(23%)
Grade  1 8(61%) 9(70%) 8(61%)
Grade  2 3(23%) 2(15%) 2(15%)
alpha 0,13 0,36 0,11
Roughness  0 2(15%) 4(30%) 4(30%)
Roughness  1 6(46%) 7(53%) 8(61%)
Roughness  2 4(30%) 2(15%) 1(8%)
alpha 0,32 0,41 0,42
Breathiness  0 5(38%) 6(46%) 5(38%)
Breathiness  1 5(38%) 4(30%) 5(38%)
Breathiness  2 3(23%) 3(23%) 3(23%)
alpha 0,72 0,52 0,48
Asthenia  0 6(46%) 11(84%) 11(84%)
Asthenia  1 6(46%) 2(15%) 2(15%)
Asthenia  2 1(8%) 0 0
alpha 0,44 0,09 0,11
Strain  0 8(61%) 9(70%) 7(53%)
Strain  1 4(30%) 4(30%) 5(38%)
Strain  2 1(8%) 0 1(8%)
alpha 0,06 0,07 0,09
Instability  0 8(61%) 10(76%) 8(61%)
Instability  1 5(38%) 3(23%) 5(38%)
Instability  2 0 0 0
alpha 0,17 0,15 0,10
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be lacking in hyperthyroidic patients due to generalized 
muscle weakness.24 
According to the clinical experience of the endo-
crinology unit, the linearity and low frequency of voice-
related complaints in our sample may be explained by their 
relative unimportance compared to the remaining symp-
toms and discomforts that are typical of hyperthyroidism, 
except for patients who use their voice professionally; in 
such cases, voice complaints receive greater attention. In 
hyperthyroidism there is hear intolerance, increased swe-
ating, mild to extreme weight loss, diarrhea, muscle weak-
ness, nervousness, extreme fatigue and hand tremors.25 
There were no statistically significant variations in 
the computer-analyzed (Praat software) fundamental fre-
quency of voice (measured in Hertz) (Chart 3). This was 
an expected result, as there was no hormonal variation 
or progression in the hyperthyroidic state, which would 
lead to edema and worsening of voice.27,28 
CONCLUSION
Our findings suggest that isotope I131 radiation 
used for treating hyperthyroidic patients due to Graves’s 
Disease does not affect voice quality, and vocal fold mo-
bility and configuration in the acute phase, and does not 
cause laryngeal inflammation.
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